Result
100%
Clinical Response
Consistent rapid improvement-even in antibiotic resistant and the most hard-to-treat infections. Including carbapenem-resistant ESKAPE pathogens
100%
Eradication of chronic, recurrent and relapsing infections
80% eradicated after the first AtbFinder-guided antibiotic selection
100% eradicated after the subsequent AtbFinder-guided treatment
50–60%
Reduction in total antibiotic exposure
Improves outcomes while reducing toxicity, C. difficile risk, and drug–drug interactions.
5-12 day
Average reduction in hospital stay
>9 days
Shorter length of stay
2-fold
Decrease in antibiotic use
Addresses the biggest
gap in susceptibility testing:
Uses real tissue-level drug concentrations, not MIC values.
Antibiotic combinations
Only AtbFinder evaluates effective antibiotic combinations
Improves antimicrobial
stewardship
Decreases broad-spectrum use and lowers selection pressure for resistance.
Same-day results
From sample to results in 6h -20h
Clinically validated across multiple studies
Sepsis
Hospital-acquired pneumonia (including VAP)
Urinary tract infections (including CAUTI)
Wound and ulcer infections
Cystic fibrosis
infections in children, the elderly, and immunocompromised patients
Mixed bacterial-fungal infections
Feature
AtbFinder is the first pure-culture-independent
non-MIC-based antibiotic selection test.
AtbFinder is a first-of-its-kind phenotypic test
that identifies antibiotics that will actually work
for each specific patient
AtbFinder is fundamentally different from both: (1) Classical culture + minimal inhibitory concentration testing (2) Molecular resistance tests (PCR/NGS)
6-20 hours
from sample to results
90-180
Antibiotics per patient — ultra-broad antibiotic profiling
Two pillars of Innovation.
01
Response of the complete polymicrobial biofilm community
02
Real tissue antibiotic concentrations
AtbFinder® — effective antibiotics from the first treatment attempt for drug-resistant and chronic infections
References
2
Tetz G, Tetz V. Evaluation of a New Culture-Based AtbFinder Test-System Employing a Novel Nutrient Medium for the Selection of Optimal Antibiotics for Critically Ill Patients with Polymicrobial Infections within 4 h. Microorganisms. 2021 May 4;9(5):990. doi: 10.3390/microorganisms9050990.
3
Tetz G, Kardava K, Vecherkovskaya M, Hahn A, Tsifansky M, Koumbourlis A, Tetz V. AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis. J Clin Microbiol. 2023 Jan 26;61(1):e0155822. doi: 10.1128/jcm.01558-22.
4
Tetz GV, Kardava KM, Vecherkovskaya MF, Tsifansky MD, Tetz VV. Treatment of chronic relapsing urinary tract infection with antibiotics selected by AtbFinder. Urol Case Rep. 2022 Dec 28;46:102312. doi: 10.1016/j.eucr.2022.102312. 2026 ASCO Annual Meeting New Paradigm for Antibiotic Selection in Hard-to-Treat Drug-Resistant Infections Following HSCT
AUA 2026
AtbFinder: A Novel Diagnostic Test That Improves Antibiotic Selection and Clinical Outcomes in UTI-Associated Cognitive Decline and Delirium in Patients with Neurodegenerative Disorders
SIDP & MAD-ID Annual Meeting
Microbial Cell Memory in Biofilms: A New Frontier for Effective Antibiotic Selection in Hard-to-Treat Drug-Resistant Infections